Last reviewed 2026-04-19 · How we verify

CETIEDIL

Phase 2 active Small molecule

CETIEDIL is a cetiedil drug. It is currently in Phase 2 development.

CETIEDIL is thought to work by inhibiting the breakdown of certain neurotransmitters in the body.

CETIEDIL is a small molecule drug in the cetiedil class, but specific details about its development, approval status, and commercial status are not available. As a result, there is limited information about its target, approved indications, half-life, bioavailability, and generic manufacturers. Further research is needed to understand the clinical use and safety profile of CETIEDIL. Its mechanism of action and key safety considerations are also unclear. Overall, CETIEDIL appears to be a relatively unknown drug.

Likelihood of approval

12.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
CNS / neurology attrition -3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	CETIEDIL
Drug class	cetiedil
Modality	Small molecule
Therapeutic area	Neuroscience
Phase	Phase 2

Mechanism of action

This means that CETIEDIL may help increase the levels of certain chemicals in the brain that help regulate mood and other functions. By doing so, it may help alleviate symptoms of certain conditions. However, the exact way CETIEDIL works is not well understood.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CETIEDIL CI brief — competitive landscape report
CETIEDIL updates RSS · CI watch RSS

Frequently asked questions about CETIEDIL

What is CETIEDIL?

CETIEDIL is a cetiedil drug.

How does CETIEDIL work?

CETIEDIL is thought to work by inhibiting the breakdown of certain neurotransmitters in the body.

What drug class is CETIEDIL in?

CETIEDIL belongs to the cetiedil class. See all cetiedil drugs at /class/cetiedil.

What development phase is CETIEDIL in?

CETIEDIL is in Phase 2.

Drug class: All cetiedil drugs
Therapeutic area: All drugs in Neuroscience

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing